Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis

Table 2

Characteristics of FOLFIRINOX treatment.

Time on FOLFIRINOX (months)
Median	4
Range	2–6
Response (no./%)
Complete response	1/5%
Partial response	16/73%
Stable disease	5/23%
Adverse events (no./%)
Peripheral neuropathy	22/100%
Peripheral neuropathy > grade 2	2/9%
Nausea and vomiting	10/45%
Nausea and vomiting > grade 2	0/0%
Diarrhea	3/14%
Diarrhea > grade 2	0/0%
Neutropenia	5/23%
Neutropenia > grade 2	3/14%
Thrombocytopenia	2/9%
Thrombocytopenia > grade 2	1/5%
Anemia	1/5%
Anemia > grade 2	0/0%